OLD National Bancorp IN raised its position in shares of Bristol-Myers Squibb Co. (NYSE:BMY) by 2.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 186,248 shares of the biopharmaceutical company’s stock after buying an additional 4,970 shares during the period. OLD National Bancorp IN’s holdings in Bristol-Myers Squibb were worth $13,698,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in the stock. IBM Retirement Fund increased its position in shares of Bristol-Myers Squibb by 1.1% in the second quarter. IBM Retirement Fund now owns 219,448 shares of the biopharmaceutical company’s stock valued at $16,627,000 after buying an additional 2,421 shares during the last quarter. Howard Capital Management increased its position in shares of Bristol-Myers Squibb by 0.7% in the second quarter. Howard Capital Management now owns 153,499 shares of the biopharmaceutical company’s stock valued at $11,290,000 after buying an additional 1,068 shares during the last quarter. Handelsbanken Fonder AB increased its position in shares of Bristol-Myers Squibb by 19.4% in the second quarter. Handelsbanken Fonder AB now owns 141,365 shares of the biopharmaceutical company’s stock valued at $10,397,000 after buying an additional 23,000 shares during the last quarter. Chevy Chase Trust Holdings Inc. increased its position in shares of Bristol-Myers Squibb by 1.1% in the second quarter. Chevy Chase Trust Holdings Inc. now owns 1,460,780 shares of the biopharmaceutical company’s stock valued at $107,440,000 after buying an additional 15,313 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Bristol-Myers Squibb by 1.9% in the first quarter. Geode Capital Management LLC now owns 13,534,575 shares of the biopharmaceutical company’s stock valued at $862,835,000 after buying an additional 254,653 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.
Bristol-Myers Squibb Co. (NYSE:BMY) traded up 1.79% during mid-day trading on Tuesday, reaching $55.64. The company’s stock had a trading volume of 4,650,104 shares. Bristol-Myers Squibb Co. has a 12-month low of $53.56 and a 12-month high of $77.12. The firm’s 50 day moving average is $56.87 and its 200-day moving average is $67.07. The company has a market cap of $92.97 billion, a PE ratio of 32.54 and a beta of 0.75.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.03. Bristol-Myers Squibb had a return on equity of 24.92% and a net margin of 16.63%. The firm had revenue of $4.90 billion for the quarter, compared to the consensus estimate of $4.60 billion. During the same quarter in the prior year, the business earned $0.53 earnings per share. The company’s revenue was up 17.2% compared to the same quarter last year. Equities analysts anticipate that Bristol-Myers Squibb Co. will post $2.62 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, November 1st. Stockholders of record on Friday, October 7th will be paid a $0.38 dividend. The ex-dividend date of this dividend is Wednesday, October 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 2.78%. Bristol-Myers Squibb’s payout ratio is 87.36%.
Several brokerages have recently weighed in on BMY. Goldman Sachs Group Inc. restated a “buy” rating and set a $75.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, September 27th. Citigroup Inc. reduced their price target on Bristol-Myers Squibb from $75.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, September 20th. Jefferies Group restated a “hold” rating and set a $57.00 price target (down from $69.00) on shares of Bristol-Myers Squibb in a report on Monday, September 12th. Barclays PLC reduced their price target on Bristol-Myers Squibb from $75.00 to $65.00 and set an “equal weight” rating for the company in a report on Friday, September 9th. Finally, Leerink Swann reaffirmed a “buy” rating and set a $75.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, September 7th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $69.91.
In other news, Director Lamberto Andreotti sold 23,200 shares of the company’s stock in a transaction dated Friday, July 8th. The stock was sold at an average price of $74.45, for a total value of $1,727,240.00. Following the sale, the director now owns 380,099 shares in the company, valued at $28,298,370.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.24% of the stock is owned by insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.